Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
William L HerringMeghan E GallagherNirmish ShahK C MorseDeirdre MladsiOlivia M DongAnjulika ChawlaJennifer W LeidingLixin ZhangClark ParamoreBiree AndemariamPublished in: PharmacoEconomics (2024)
Our analysis of lovo-cel gene therapy compared with common care for patients in the US with SCD with recurrent VOEs estimated meaningful improvements in survival, quality of life, and other clinical outcomes accompanied by increased overall costs for the health care system and for broader society. The predicted economic value of lovo-cel gene therapy was influenced by uncertainty in long-term clinical effects and by positive spillover effects on patient productivity and caregiver burden.
Keyphrases
- gene therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- healthcare
- prognostic factors
- palliative care
- dna methylation
- gene expression
- case report
- patient reported outcomes
- copy number
- pain management
- health insurance
- genome wide identification
- endovascular treatment